Express Pharma
Home  »  Latest Updates  »  Merial and Zoetis in strategic agreement

Merial and Zoetis in strategic agreement


Agreement expands Merial portfolio to include 15 new products, making it a key player in the dairy cattle market in India

Merial, the animal health division of Sanofi, and Zoetis India, a subsidiary of Zoetis, have entered into an exclusive marketing and distribution agreement for medicines and vaccines for dairy cattle in India. Merial will market and sell Zoetis’ products, including global/ local brands such as Bovical, Lutalyse, Xnel Dectomax and vaccines like Rispoval and Spirovac. The products will be marketed by Merial India beginning in April 2016. Financial details of the agreement were not disclosed.

In India, Merial has a diversified local portfolio of over 50 brands comprising of vaccines, therapeutics and nutritional products for ruminants, poultry and pets.

Sandeep Karkhanis, Country Manager, Merial India said, “For Merial, this agreement reinforces the strategic importance of India and the animal health market in the country. We plan to keep our focus and investment in product innovation, acquisitions and alliances, growth areas and services to meet the evolving needs of our customers.”

Ketan Dhamanaskar, Managing Director, India, GM South Asia, Zoetis, said, “Zoetis India will be able to focus its field force and resources on building a stronger presence and market leadership in the poultry and companion animal sectors in India, which grew at 18.6 per cent and 12.8 per cent respectively in 20155.”

EP News BureauMumbai

Comments are closed.